Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial

X
Trial Profile

Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aviptadil (Primary) ; Sodium chloride
  • Indications Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jan 2024 Status changed from recruiting to discontinued. ( Difficulties recruiting participants for the Aviptadil study as there are nowadays very fewhospitalized COVID patients. Continuous screening has been carried out but none of the patientsmet the eligibility criteria for the study. )
    • 07 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
    • 07 Feb 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top